Brainsway

Company Overview

Snapshot

Founded in January 2003 by Avner Hagai, Yiftach Roth, David Zacut, and Abraham Zangen, Brainsway operates with 51–200 employees. The company has raised $79.95 million across six funding rounds from six investors. In September 2024, Brainsway announced a private placement with Valor Equity Partners.

Business overview

Brainsway develops advanced noninvasive neurostimulation treatments for mental health disorders, leveraging its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology. The company's technology is based on patents filed by the US National Institutes of Health (NIH), for which Brainsway holds an exclusive license. Its solutions are FDA cleared for treating major depressive disorder, obsessive-compulsive disorder (OCD), and smoking addiction, and are approved in Canada for major depressive disorder. Brainsway serves the healthcare industry, including hospitals, clinics, and healthcare providers, operating within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In September 2024, Brainsway announced a significant expansion on the U.S. East Coast, indicating a strategic move to broaden its market reach and accessibility for its Deep TMS™ treatments. This expansion suggests a strong commercial momentum and a commitment to increasing the availability of its neurostimulation therapies, which could lead to accelerated adoption and revenue growth for the company.

Company Intelligence Q&A

What was a key financial development for Brainsway in September 2024?

In September 2024, Brainsway announced a private placement of US$20 million with Valor Equity Partners.

What recent regulatory milestone did Brainsway achieve for its Deep TMS technology?

In September 2025, BrainsWay received FDA clearance for an accelerated Deep TMS protocol for the non-invasive treatment of Major Depressive Disorder (MDD).

How is Brainsway expanding access to its Deep TMS technology for U.S. military service members?

In September 2023, BrainsWay broadened access to Deep TMS™ for U.S. military service members through an expanded partnership with Katie’s Way Plus.

What strategic partnership did Brainsway forge in the Northeast U.S.?

In September 2023, BrainsWay forged a strategic partnership with a treatment provider in the Northeast U.S. to expand the availability of its therapies.

What is Brainsway's strategy for market penetration in East Asia?

In October 2024, BrainsWay further penetrated East Asia with the placement of 15 additional Deep TMS™ systems in Taiwan and South Korea, expanding its reach in the region.